stoke therapeutics inc - STOK
STOK
Close Chg Chg %
31.82 -0.08 -0.25%
Closed Market
31.74
-0.08 (0.25%)
Volume: 421.45K
Last Updated:
Dec 31, 2025, 4:00 PM EDT
Company Overview: stoke therapeutics inc - STOK
STOK Key Data
| Open $31.68 | Day Range 31.45 - 32.50 |
| 52 Week Range 5.35 - 38.62 | Market Cap $1.81B |
| Shares Outstanding 57.12M | Public Float 46.32M |
| Beta 1.11 | Rev. Per Employee N/A |
| P/E Ratio 48.22 | EPS $0.71 |
| Yield 0.00% | Dividend N/A |
| EX-DIVIDEND DATE | SHORT INTEREST N/A |
| AVERAGE VOLUME 872.64K |
STOK Performance
| 1 Week | -0.56% | ||
| 1 Month | 2.82% | ||
| 3 Months | 24.18% | ||
| 1 Year | 187.76% | ||
| 5 Years | -48.75% |
STOK Analyst Ratings
- Sell
- Under
- Hold
- Over
- Buy
Number of Ratings
9
Full Ratings ➔
About stoke therapeutics inc - STOK
Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. It offers a wide range of relevant tissues including the central nervous system, eye, kidney, and liver. The company was founded by Isabel Aznarez and Adrian R. Krainer in June 2014 and is headquartered in Bedford, MA.
STOK At a Glance
Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford, Massachusetts 01730
| Phone | 1-781-430-8200 | Revenue | 36.56M | |
| Industry | Biotechnology | Net Income | -88,981,000.00 | |
| Sector | Health Technology | 2024 Sales Growth | 316.344% | |
| Fiscal Year-end | 12 / 2025 | Employees | 128 | |
| View SEC Filings |
STOK Valuation
| P/E Current | 48.219 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 16.296 |
| Price to Book Ratio | 2.602 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.957 |
| Enterprise Value to Sales | 10.492 |
| Total Debt to Enterprise Value | 0.012 |
STOK Efficiency
| Revenue/Employee | 285,585.938 |
| Income Per Employee | -695,164.063 |
| Receivables Turnover | 52.221 |
| Total Asset Turnover | 0.146 |
STOK Liquidity
| Current Ratio | 5.811 |
| Quick Ratio | 5.811 |
| Cash Ratio | 5.417 |
STOK Profitability
| Gross Margin | 87.848 |
| Operating Margin | -277.314 |
| Pretax Margin | -243.417 |
| Net Margin | -243.417 |
| Return on Assets | -35.60 |
| Return on Equity | -45.797 |
| Return on Total Capital | -38.059 |
| Return on Invested Capital | -44.961 |
STOK Capital Structure
| Total Debt to Total Equity | 2.085 |
| Total Debt to Total Capital | 2.042 |
| Total Debt to Total Assets | 1.758 |
| Long-Term Debt to Equity | 1.071 |
| Long-Term Debt to Total Capital | 1.049 |
- Income Statement
- Balance Sheet
- Cash Flow Statement
Annual Financials for Stoke Therapeutics Inc - STOK
Collapse All in section
| All values USD millions. | 2021 | 2022 | 2023 | 2024 | 5-year trend |
|---|---|---|---|---|---|
Sales/Revenue
| - | 12.40M | 8.78M | 36.55M | |
Sales Growth
| - | - | -29.22% | +316.34% | - |
Cost of Goods Sold (COGS) incl D&A
| 2.23M | 3.54M | 4.73M | 4.44M | |
COGS excluding D&A
| - | - | - | - | - |
Depreciation & Amortization Expense
| 2.23M | 3.54M | 4.73M | 4.44M | |
Depreciation
| 2.23M | 3.54M | 4.73M | 4.44M | |
Amortization of Intangibles
| - | - | - | - | - |
COGS Growth
| +15.78% | +58.52% | +33.78% | -6.07% | |
Gross Income
| (2.23M) | 8.87M | 4.05M | 32.11M | |
Gross Income Growth
| -15.78% | +497.76% | -54.33% | +692.72% | |
Gross Profit Margin
| - | +71.50% | +46.14% | +87.85% |
| 2021 | 2022 | 2023 | 2024 | 5-year trend | |
|---|---|---|---|---|---|
SG&A Expense
| 83.83M | 113.23M | 118.82M | 133.49M | |
Research & Development
| 53.19M | 76.29M | 79.76M | 86.96M | |
Other SG&A
| 30.64M | 36.94M | 39.06M | 46.53M | |
SGA Growth
| +64.00% | +35.06% | +4.94% | +12.34% | |
Other Operating Expense
| - | - | - | - | - |
Unusual Expense
| - | - | - | - | - |
EBIT after Unusual Expense
| (86.06M) | (104.36M) | (114.77M) | (101.37M) | |
Non Operating Income/Expense
| 260.00K | 3.29M | 10.07M | 12.39M | |
Non-Operating Interest Income
| 120.00K | 3.12M | 9.91M | 12.64M | |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Interest Expense
| - | - | - | - | - |
Interest Expense Growth
| - | - | - | - | - |
Gross Interest Expense
| - | - | - | - | - |
Interest Capitalized
| - | - | - | - | - |
Pretax Income
| (85.81M) | (101.07M) | (104.70M) | (88.98M) | |
Pretax Income Growth
| -64.24% | -17.79% | -3.59% | +15.01% | |
Pretax Margin
| - | -814.73% | -1,192.47% | -243.42% | |
Income Tax
| - | - | - | - | - |
Income Tax - Current - Domestic
| - | - | - | - | - |
Income Tax - Current - Foreign
| - | - | - | - | - |
Income Tax - Deferred - Domestic
| - | - | - | - | - |
Income Tax - Deferred - Foreign
| - | - | - | - | - |
Income Tax Credits
| - | - | - | - | - |
Equity in Earnings of Affiliates
| - | - | - | - | - |
Other After Tax Income (Expense)
| - | - | - | - | - |
Consolidated Net Income
| (85.81M) | (101.07M) | (104.70M) | (88.98M) | |
Minority Interest Expense
| - | - | - | - | - |
Net Income
| (85.81M) | (101.07M) | (104.70M) | (88.98M) | |
Net Income Growth
| -64.24% | -17.79% | -3.59% | +15.01% | |
Net Margin Growth
| - | -814.73% | -1,192.47% | -243.42% | |
Extraordinaries & Discontinued Operations
| - | - | - | - | - |
Discontinued Operations
| - | - | - | - | - |
Net Income After Extraordinaries
| (85.81M) | (101.07M) | (104.70M) | (88.98M) | |
Preferred Dividends
| - | - | - | - | - |
Net Income Available to Common
| (85.81M) | (101.07M) | (104.70M) | (88.98M) | |
EPS (Basic)
| -2.3355 | -2.5983 | -2.3798 | -1.6475 | |
EPS (Basic) Growth
| -49.71% | -11.25% | +8.41% | +30.77% | |
Basic Shares Outstanding
| 36.74M | 38.90M | 43.99M | 54.01M | |
EPS (Diluted)
| -2.3355 | -2.5983 | -2.3798 | -1.6475 | |
EPS (Diluted) Growth
| -49.71% | -11.25% | +8.41% | +30.77% | |
Diluted Shares Outstanding
| 36.74M | 38.90M | 43.99M | 54.01M | |
EBITDA
| (83.83M) | (100.82M) | (110.04M) | (96.93M) | |
EBITDA Growth
| -64.00% | -20.26% | -9.15% | +11.92% | |
EBITDA Margin
| - | -812.74% | -1,253.35% | -265.16% |
Snapshot
| Average Recommendation | BUY | Average Target Price | 35.714 | |
| Number of Ratings | 9 | Current Quarters Estimate | -0.752 | |
| FY Report Date | 03 / 2026 | Current Year's Estimate | -3.058 | |
| Last Quarter’s Earnings | -0.71 | Median PE on CY Estimate | N/A | |
| Year Ago Earnings | 0.16 | Next Fiscal Year Estimate | -2.461 | |
| Median PE on Next FY Estimate | N/A |
Earnings Per Share
| This Quarter | Next Quarter | This Fiscal | Next Fiscal | |
|---|---|---|---|---|
| # of Estimates | 6 | 6 | 10 | 7 |
| Mean Estimate | -0.75 | -0.77 | -3.06 | -2.46 |
| High Estimates | -0.69 | -0.72 | -2.49 | -2.04 |
| Low Estimate | -0.83 | -0.84 | -3.65 | -3.20 |
| Coefficient of Variance | -8.22 | -7.44 | -10.68 | -16.82 |
Analysts Recommendations
| Current | 1 Month Ago | 3 Months Ago | |
|---|---|---|---|
| BUY | 9 | 9 | 10 |
| OVERWEIGHT | 0 | 0 | 0 |
| HOLD | 0 | 0 | 1 |
| UNDERWEIGHT | 0 | 0 | 0 |
| SELL | 0 | 0 | 0 |
| MEAN | Buy | Buy | Buy |
SEC Filings for Stoke Therapeutics Inc - STOK
| Filing Date | Type | Category | Amended |
|---|---|---|---|
| No results | |||
Insider Actions for Stoke Therapeutics Inc - STOK
| Date | Name | Shares | Transaction | Value |
|---|---|---|---|---|
| Mar 21, 2025 | Thomas Leggett Chief Financial Officer | 59,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | 48,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | 72,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | 31,565 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.27 per share | 261,042.55 |
| Mar 21, 2025 | Jonathan Allan GENERAL COUNSEL & CORP SEC | 33,510 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.67 per share | 290,531.70 |
| Mar 21, 2025 | Barry S. Ticho CHIEF MEDICAL OFFICER | 43,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Barry S. Ticho CHIEF MEDICAL OFFICER | 64,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Barry S. Ticho CHIEF MEDICAL OFFICER | 60,629 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.27 per share | 501,401.83 |
| Mar 21, 2025 | Barry S. Ticho CHIEF MEDICAL OFFICER | 63,962 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.67 per share | 554,550.54 |
| Mar 21, 2025 | Arthur A. Levin Director | 4,842 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Thomas Leggett Chief Financial Officer | 89,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Arthur O. Tzianabos Interim Executive Chair; Director | 122,651 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Ian Frederick Smith Interim CEO; Director | 238,420 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Edward M. Kaye Director | 144,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Edward M. Kaye Director | 216,000 | Grant, award or other acq pursuant to Rule 16b-3(d) | 0.00 |
| Mar 21, 2025 | Edward M. Kaye Director | 139,346 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.27 per share | 1,152,391.42 |
| Mar 21, 2025 | Edward M. Kaye Director | 148,253 | Open market or private sale of non-derivative or derivative security Non-derivative transaction at $8.67 per share | 1,285,353.51 |